Psyence Biomedical Ltd. is a holding company, which engages in the development and commercialization of pharmaceutical products in neurology. The company is headquartered in Toronto, Ontario and currently employs 12 full-time employees. The company went IPO on 2021-12-10. The firm is focused on developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine. The company is dedicated to addressing unmet mental health needs, particularly in palliative care. Its ongoing Phase IIb psilocybin clinical trial in Australia focuses on adjustment disorder in patients diagnosed with cancer.
Follow-Up Questions
Psyence Biomedical Ltd (PBM) 的市盈率是多少？
Psyence Biomedical Ltd 的市盈率是 2.3826
Psyence Biomedical Ltd 的 CEO 是谁？
Mr. Marc Balkin 是 Psyence Biomedical Ltd 的 Chief Executive Officer，自 2021 加入公司。
PBM 股票的价格表现如何？
PBM 的当前价格为 $2.74，在上个交易日 decreased 了 0%。
Psyence Biomedical Ltd 的主要业务主题或行业是什么？
Psyence Biomedical Ltd 属于 Biotechnology 行业，该板块是 Health Care
